Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 72INDUSTRY 14NETWORK 2OTHER_GOV 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 26CNS 18Other hematologic neoplasm 15Sarcoma 14Gynecologic 7Genitourinary 5Plasma cell 2Myeloid 2Classical hematology 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 48Bortezomib 22Lenalidomide 20Cyclophosphamide 20daratumumab 18Calcium Dobesilate 15Melphalan 13Thalidomide 12carfilzomib 9pomalidomide 7Prednisone 7dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6isatuximab 5Filgrastim 5Vincristine 4Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2belantamab mafodotin 2Steroids 2Stem Cell Transplantation 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Granulocyte Colony-Stimulating Factor × Plasma cell × Clear all
NCT00040937 2016-12-08

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

SWOG Cancer Research Network

Phase 2 Completed
147 enrolled 6 charts
Plasma cell

Multiple Myeloma

NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

SWOG Cancer Research Network

Phase 3 Terminated
19 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡